24 August 2023 08:00
Cell Impact Q2 2023: Temporary lower level of activity and cost reduction program
Cell Impact AB (Nasdaq First North GM: CI) reports the following summary for the second quarter 2023.
Net sales during the second quarter totaled SEK 17.2 million (20.4). The operating profit, which dropped to –27.1 MSEK (–21.8), is disappointing and contrary to previously expected development.
Before the second quarter, we saw indications of significantly increased demand during the second half-year and we expected a good full year. Instead, we received indications that involve delays in orders. Against this backdrop, in July, we announced a cost reduction program to adapt our organization and costs to the lower levels of flow plate production that we now expect. Based on the continued progress in the development of the industry combined with our customers’ leading market positions we consider the current situation to be a temporary adjustment in production levels.
There is great interest in Cell Impact’s expertise and scalable production offering, where Cell Impact FormingTM plays an important role, providing the possibility to add capacity comparatively quickly. Cell Impact has a sharp focus on converting its strong pipeline of projects into new businesses.
Cell Impact’s financial targets
Sales target 2025: SEK 200–250 million
Sales target 2028: >SEK 600 million
Profitability targets: EBITDA >15% in medium term
The EBITDA break-even is still expected to be reached in 2025 driven by greatly improved productivity through Cell Impact’s Phase II program and larger sales volumes. In the longer term, Cell Impact sees potential for substantially higher EBITDA margins than the company’s profitability targets for the medium term.
Financial Summary
- Net sales totaled SEK 17.2 million (20.4).
- Operating profit (EBIT) was SEK –27.1 million (–21.8).
- The Group’s result after financial items was SEK –28.5 million (–22.2).
- Earnings per share attributable to the Parent Company’s shareholders before and after dilution totaled SEK –0.38 (–0.29).
- Debt/equity ratio was 76 percent (87) on the balance sheet date.
- Cash flows from operating activities amounted to SEK –24.2 million (–40.0).
- On the balance sheet date, the Group’s cash and cash equivalents totaled SEK 79.5 million (219.7).
This information is inside information that Cell Impact AB is obliged to make public pursuant to the EU Market Abuse Regulation.
IR Contact
Pär Teike
CEO, Cell Impact AB
+46 73-024 06 84 or paer.teike@cellimpact.com
For more information, please contact:
Stefan Axellie
CFO, Cell Impact AB
+46 70-343 46 55 eller stefan.axellie@cellimpact.com
About Cell Impact
Cell Impact AB (publ) is a global supplier of advanced flow plates to fuel cell and electrolysis manufacturers. The company has developed and patented a unique method for high velocity forming, Cell Impact Forming™ which is significantly more scalable and cost-efficient compared to conventional forming methods. Cell Impact Forming is an environmentally friendly forming technology that consumes no water and very little electrical power.
The Cell Impact share is listed on Nasdaq First North Growth Market and FNCA Sweden AB is the company’s Certified Advisor (CA). Contact info: +46 8-528 00 399 or info@fnca.